Partnership for DSCSA Governance

Who is PDG?

PDG is an independent, balanced, sector-neutral nonprofit industry governance body that supports the secure, electronic, interoperable tracing, and verification of prescription drugs in the U.S. supply chain, as required by the Drug Supply Chain Security Act (DSCSA). PDG's membership includes leading authorized manufacturers, repackagers, wholesalers, third-party logistics providers, and dispensers (hospitals and retail and independent pharmacies), as well as leading industry trade associations and technical experts. Together, these members are working to establish a comprehensive vision for industry's implementation of secure, electronic systems and processes for drug traceability in the U.S. For additional information, visit www.DSCSAgovernance.org.

Why Does Governance Matter?

PDG plays a pivotal role in two overarching functions:

1. Industry Decision-Making: PDG acts as the platform for trading partners to define and harmonize their interoperability business requirements under DSCSA, setting minimum standards for commercial DSCSA services.
2. Public-Private Collaboration: PDG serves as the nexus where industry stakeholders, the FDA, and state regulators collaborate to align their expectations and facilitate interoperable systems for investigations and recalls.

Who Can Participate In The Governance Body?

PDG membership is reserved for key pharmaceutical supply chain entities, known as "trading partners" under DSCSA, who have legal obligations. These members, which include authorized manufacturers, repackagers, wholesalers, third-party logistics providers, and dispensers, possess full decision-making authority. PDG's strategic direction is managed by a 14-member Board, elected by the membership, overseeing day-to-day operations. In addition to the general membership, PDG recognizes two types of members who hold voting rights and privileges: (1) Trading Partner Members: This category includes any trading partner, as defined in the DSCSA, who holds authorization under the DSCSA. They are eligible for full general membership rights and privileges. And (2) Association Members: Association members encompass trade associations or societies whose membership primarily consists of trading partners as defined in the DSCSA, along with professional societies that represent healthcare providers. These members also enjoy full voting rights and privileges within PDG. Furthermore, PDG extends an invitation to technical or process experts, including thought leaders and service providers, to actively participate in all work groups where participation is not restricted to general members. This inclusive approach fosters collaboration and expertise sharing among industry stakeholders.

Member Benefits

- Direct Input: Members have a direct voice in shaping the industry's business requirements outlined in the PDG Blueprint.
- Engagement: Access to work groups allows for discussions on industry challenges in DSCSA maintenance and compliance.

- Public-Private Partnership: PDG provides a way for members to communicate ongoing challenges to FDA.
- Industry Leadership: PDG offers an opportunity to assume a leadership role within the industry.

2026 Activities

Since its inception, PDG has identified and built numerous resources to support interoperability, including most importantly, our *Blueprint for Interoperability*. With a significant portion of the industry under full compliance expectations in 2026, PDG is shifting its focus to concentrate less on proactive development of resources more on responsive resolutions of challenges identified by industry through the PDG Change Request process. Specifically, PDG will focus its 2026 efforts on:

- Maintaining public access to *PDG Blueprint* and related documents.
- Maintaining the *Blueprint* Change Request process.
- Providing a forum for interaction and collaboration with FDA and state regulators on DSCSA matters generally.
- Providing a forum for interaction and collaboration with FDA and state regulators on technical interoperability matters.
- Providing a forum for industry members and technology providers to work through technical interoperability challenges.

Membership Dues

Recognizing that PDG's focus is shifting in 2026, as noted above, the Board anticipates PDG's responsive activities will be less resource-intensive than past, more proactive activities. The Board proposed – and voting members approved – an approximate 70 percent decrease in the 2026 total budget, and, consistent with the reduced scope and budget, an approximate 75 percent decrease in 2026 dues. The updated dues for 2026 are reflected in the tables below.

The membership dues set out below are proposed to be similar (but not identical) among sectors and account for ability-to-pay, based on annual U.S. pharmaceutical revenue. A small-business rate is available to trading partners with 25 or fewer full-time employees. A single fee applies to Association Members, and technical expert dues are tiered by number of employees.

	Proposed FY 2026 MEMBERSHIP DUES				
	Manufacturers/ Repackagers	**Wholesalers/ 3PLs**	**Dispensers**	**Associations**	**Technical Experts**
Tier 1	$4,800	$4,800	$4,800	$50	$1,400
Tier 2	$2,800	$2,800	$1,400		$700
Tier 3	$950	$475	$250		
Small Business	$100	$100	$50		$100

	TIER DEFINITIONS				
	Manufacturers/ Repackagers	**Wholesalers/ 3PLs**	**Dispensers**	**Associations**	**Technical Experts**
Tier 1	> $10 B	> $10 B	> $10 B	N/A	101+ EEs
Tier 2	$1 B - $10 B	$1 B - $10 B	$1 B - $10 B		26-100 EEs
Tier 3	< $1 B	< $1 B	< $1 B		
Small Business	25 or fewer full-time employees				25 or fewer EEs